Brief: Everest Medicines Announces European Commission Grants Approval Of Kinpeygo For Adults With Primary IgA Nephropathy To Our Partner Calliditas Therapeutics
18/07/2022 01:17
July 17 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES ANNOUNCES EUROPEAN COMMISSION GRANTS
APPROVAL
OF KINPEYGO® FOR ADULTS WITH PRIMARY IGA NEPHROPATHY TO OUR
PARTNER CALLIDITAS THERAPEUTICS
Source text for Eikon: ID:nPn1mTntpa
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations